Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262412086 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tal Kan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novocure Ltd., Haifa 3190500, Israel. Hauptthemen laut MEDLINE: Macrophages, Tumor-Associated Macrophages. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novocure Ltd..
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novocure Ltd., Haifa 3190500, Israel.
ORCID-Profile: Tal Kan, Yiftah Barsheshet, Tharwat Haj Khalil, Boris Brant, Kerem Ben-Meir, Moshe Giladi, Yoram Palti
Förderung
- Novocure Ltd.
Zitieren
APA
Kan, T., Barsheshet, Y., Haj Khalil, T., Brant, B., Voloshin, T., Ben-Meir, K., Zisman Rosen, S., Giladi, M., Weinberg, U., & Palti, Y. (2025). Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields). International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412086
Vancouver
Kan T, Barsheshet Y, Haj Khalil T, Brant B, Voloshin T, Ben-Meir K, et al. Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields). International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412086
BibTeX
@article{Kan2025,
author = {Kan, Tal and Barsheshet, Yiftah and Haj Khalil, Tharwat and Brant, Boris and Voloshin, Tali and Ben-Meir, Kerem and Zisman Rosen, Simona and Giladi, Moshe and Weinberg, Uri and Palti, Yoram},
title = {Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262412086}
}
EUVIMED